Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179872 | 0.91 | ESR2 (0.72) | ESR1ESR2NR1H2HDAC6PKM | |
| SCHEMBL1641841 | 0.91 | ESR1 (0.72) | ESR1ESR2NR1H2HDAC6PKM | |
| SCHEMBL29754116 | 0.91 | ESR1 (0.72) | ESR1ESR2NR1H2HDAC6PKM | |
| Hydrochloric Acid SCHEMBL1639774 | 0.90 | ESR1 (0.70) | ESR1ESR2NR1H2HDAC6PKM | |
| SCHEMBL719456 | 0.83 | ESR1 (0.56) | ESR1ESR2NR1H2HDAC6PKM | |
| SCHEMBL373697 | 0.83 | ESR2 (0.83) | ESR1ESR2HDAC6ABHD6CA1 | |
| SCHEMBL3353692 | 0.82 | ESR1 (0.60) | ESR1ESR2NR1H2HDAC6PKM | |
| SCHEMBL566629 | 0.81 | ESR1 (0.58) | ESR1ESR2HDAC6PKMABHD6 | |
| SCHEMBL1787936 | 0.81 | ABHD6 (0.60) | ESR1ESR2HDAC6PKMABHD6 | |
| SCHEMBL7849236 | 0.81 | ESR2 (0.58) | ESR1ESR2HDAC6PKMABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307409-A1 | ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2024-09-19 | — | — | US | disclosed |
| EP-4342878-A1 | ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022188823-A1 | TRICYCLIC HPK1 INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2022-09-15 | — | — | WO | disclosed |
| EP-2938345-B1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING CO (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9284277-B2 | Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2610258-B1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-5827849-A | HAVING INHIBITORY EFFECT ON INFLAMMATION AND BONE DEGRADATION, ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASIS-INHIBITING EFFECT | KARL THOMAE GMBH (DE) | 1998-10-27 | — | — | US | disclosed |
| EP-0612741-B1 | Cyclic derivatives, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1998-06-10 | — | — | EP | disclosed |
| EP-0777667-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | Dr. Karl Thomae GmbH (DE) | 1997-06-11 | — | — | EP | disclosed |
| US-5612335-A | ANTICOAGULANTS; COMBATING/PREVENTING DISEASES WHERE CELL AGGREGATES OCCUR OR CELL-MATRIX INTERACTIONS PLAY A PART | KARL THOMAE GMBH (DE) | 1997-03-18 | — | — | US | disclosed |
| US-5519036-A | IMIDAZOLIDINONES, ANTICOAGULANTS, CELL AGGREGATION PREVENTION | KARL THOMAE GMBH (DE) | 1996-05-21 | — | — | US | disclosed |
| WO-1996005194-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | DR. KARL THOMAE GMBH (DE) | 1996-02-22 | — | — | WO | disclosed |
| WO-1996002514-A1 | UREA AND CARBAMIC ACID DERIVATIVES, DRUGS CONTAINING THESE COMPOUNDS, AND PROCESS FOR THEIR PREPARATION | DR. KARL THOMAE GMBH (DE) | 1996-02-01 | — | — | WO | disclosed |
| EP-0612741-A1 | Cyclic derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | HTR2C, HTR2A, HTR5A | ESR1 772/4885ESR2 489/4885NR1H2 612/4885 |
| US-20240307409-A1 | ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF | PRMT1, PRMT7, PRMT8 | ESR1 4186/4885ESR2 3358/4885NR1H2 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.